Attached files

file filename
10-Q - FORM 10-Q - GALECTIN THERAPEUTICS INCd402747d10q.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR33.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex312.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex321.htm
EX-10.3 - EMPLOYMENT AGREEMENT - GALECTIN THERAPEUTICS INCd402747dex103.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR6.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR9.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR2.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR5.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR3.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR1.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR7.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR8.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR4.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR21.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR14.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR17.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR23.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR29.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR32.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR18.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR30.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR10.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR24.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR20.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR15.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR28.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR13.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR16.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR19.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR27.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR12.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR11.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR25.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR31.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR22.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex322.htm
v2.4.0.6
Stock-Based Compensation - Additional Information (Detail) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 147 Months Ended
Aug. 31, 2012
May 31, 2012
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Employee
Sep. 30, 2011
Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost     $ 6,125,000   $ 6,125,000   $ 6,125,000
Unvested option     1,514,863   1,514,863   1,514,863
Unrecognized compensation cost, recognition period         3 years 8 months 12 days    
Weighted-average grant date fair value of options grant     $ 1.89 $ 1.00 $ 1.78 $ 1.02  
Stock Option expected to vest only upon achievement of certain market conditions       166,668   166,668  
Annualized volatility         117.00% 121.00% 119.00%
Annualized risk free rate         0.84% 1.91% 1.87%
Expected life         5 years 4 months 24 days 5 years 1 month 6 days 5 years 1 month 6 days
Additional stock-based compensation expense     172,000   271,000 63,000  
Number of employees, options grant modified         4    
Number of employees, cashless exercise terms modified         1    
Initial option exercisable days post-employment before modification         90 days    
Common stock granted to a consultant, shares 4,348 7,000          
Common stock granted to a consultant, amount 10,000 16,000          
Monte Carlo Option Pricing Model
             
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation cost       1,006,000   1,006,000  
Unrecognized compensation cost, recognition period           5 years 6 months  
Annualized volatility           110.00%  
Annualized risk free rate           3.50%  
Expected life           10 years  
Scenario 1
             
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock Option expected to vest only upon achievement of certain market conditions       83,334   83,334  
Required Market capitalization for vesting stock option           5,000,000,000  
Scenario 2
             
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock Option expected to vest only upon achievement of certain market conditions       83,334   83,334  
Required Market capitalization for vesting stock option           $ 10,000,000,000